Gilead Sciences and Kymera Therapeutics form exclusive agreement for option and license

Gilead Sciences is a leading biopharmaceutical company that focuses on research and development in various therapeutic areas, including virology, HIV, viral hepatitis, COVID-19, emerging viruses, oncology, and inflammation. The company’s pipeline is robust, and it prides itself on its commitment to scientific research and innovation.

The research funding programs at Gilead Sciences are extensive and cover a wide range of areas, including the Research Scholars Program, External-Sponsored Research, Virology RFP Opportunities, Oncology RFP Opportunities, Inflammation RFP Opportunities, Community-Based Participatory Research, Research Publications, Clinical Trials, and Diversity in Clinical Trials.

When it comes to medicines, Gilead Sciences prioritizes patient safety, anti-counterfeiting measures, consumer product safety, reporting adverse events, and ensuring medication access for patients in the U.S. through patient access programs, managed access, and authorized distributors.

The company also places a strong emphasis on corporate responsibility, with a focus on Environmental, Social, and Governance (ESG) performance, including ESG focus areas, ESG frameworks and reporting, and sustainability initiatives to promote health equity. Giving@Gilead is an essential part of the company’s corporate giving strategy, with programs like Strategic Initiatives, All4Liver, Asia Pacific Rainbow Grant, COMPASS Initiative, HepConnect, HIV Age Positively, RADIAN, and more aimed at elevating health equity and supporting communities.

Gilead Sciences fosters a community of inclusion and diversity through various employee resource groups such as GAIN, Gileados, GLOBE, GVET, Pride Alliance, and Women at Gilead. These groups play a vital role in advancing diversity within the company and supporting employees from all backgrounds.

The company also invests in medical education to ensure that healthcare professionals have the latest information and resources to provide the best care for patients. Through stories and narratives, Gilead Sciences highlights the impact of its work on individuals and communities, showcasing the importance of its mission and values.

Gilead Sciences is led by a team of experienced professionals, including Daniel O’Day, Andrew Dickinson, Stacey Ma, Dietmar Berger, Flavius Martin, Jyoti Mehra, Johanna Mercier, Cindy Perettie, and Deborah H. Telman. The Board of Directors, headed by Daniel O’Day and including members like Jacqueline K. Barton, Jeffrey A. Bluestone, and others, plays a crucial role in guiding the company’s strategic direction and ensuring its success.